Clinical Trials Browser

Phase 3 × letermovir × 90 days × Clear all

NCT05711667 2026-02-24

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms